Septerna (SEPN) Files for Proposed IPO

Septerna (NASDAQ: SEPN) has filed for a proposed IPO.

The company describes itself as: "We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex PlatformTM. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases."

J.P. Morgan, TD Cowen, Cantor and Wells Fargo Securities will serve as underwriters.

You May Also Be Interested In

• SpaceX (SPCX) Indicated to Open at $174
• JM Group Limited (JMG) halted, news pending
• TD Cowen on Aptiv PLC. (APTV): 'Positive Takeaways From CEO/CSO Lunch'